Medicines for All Institute’s Post

As many in the TB community prepare to gather in Paris next week for the International Union Against Tuberculosis and Lung Disease (The Union) Conference, M4ALL is pleased to share our work on improving the manufacturing processes of active pharmaceutical ingredients (API) for priority TB drugs: bedaquiline, pretomanid, sutezolid and OPC-167832. These improved processes have the potential to lower raw material costs and improve manufacturability of these drugs. All of the processes are freely available and published open access on our website: https://lnkd.in/dsA6yFcs. If you are interested in partnering with us to use this work, please reach out to the team at m4all@vcu.edu. We will provide spotlights on each of these projects leading up to the conference next week: Bedaquiline: M4ALL developed two processes that demonstrate the potential to reduce the raw material cost for the active pharmaceutical ingredient (API) of bedaquiline fumarate ("bedaquiline"). Project Details: https://lnkd.in/dSb-5XHS Pretomanid: M4ALL worked with several collaborators whose collective improvements to the API synthetic process could provide a safer route to a key intermediate and allow for the use of commodity starting materials, thus providing the API at lower raw material cost. Project Details: https://lnkd.in/dQeRZX4S Sutezolid: M4ALL made improvements to the synthesis of a key intermediate of sutezolid which could lower raw material costs of the API. Project Details: https://lnkd.in/dzEPX3Q9 OPC-167832: M4ALL developed a concise process to prepare the key dihydroquinolone intermediate used to make the API by using commodity raw materials. Project Details: https://lnkd.in/d39vBQYG #tuberculosis #bedaquiline #pretomanid #sutezolid #AccesstoMedicine #GlobalHealth #UnionConf2023

Medicines for All Global Health Portfolio | Medicines for All Institute

medicines4all.vcu.edu

To view or add a comment, sign in

Explore topics